cyklabil and Uterine-Hemorrhage

Clinical and laboratory study was carried out on 28 women, aged 47,80 years on the average, with uterine bleedings during the premenopausal phase of climacterium and accompanying neurovegetative climacteric symptoms. A cyclic preparation, containing 2 mg of estradiol-17 valerate in the first 11 tablets and the same dose of estrogen with supplement of 0.5 mg of norgestrel in the following 10 tablets was used for a period of 3 months(84 cycles in all). The preparation eliminated efficiently climacteric symptoms in addition to its assurance provision of stable clinical characteristic of succeeding pseudomenstrual symptoms cycles. The preparation did not induce increased thrombogenic risk, because the basic hemostatic indices before and after treatment were not changed. Lipid profile was not altered substantially as there was a favourable tendency to its occurrence in antiatherogenic direction (a reduction of LDL- and VLDL-cholesterol).

Topics: Climacteric; Contraceptives, Oral, Combined; Drug Evaluation; Estradiol; Female; Hemostasis; Humans; Lipids; Menopause; Middle Aged; Norgestrel; Uterine Hemorrhage